$TTI

Thiogenesis Therapeutics (TTI) received FDA clearance to test TTI-0102 in nephropathic cystinosis. The open-label pilot study at Emory will assess safety, tolerability, and pharmacokinetics in ~6 adults, with topline data expected in Q1 2027. This milestone aligns with the company's orphan-disease strategy, according to the company.

TETRA Technologies amended its term loan agreement, reducing the interest rate to SOFR+5.00% from SOFR+5.75%, extending maturity to 2030, and deferring amortization payments until 2028. The changes aim to improve liquidity and financial flexibility, according to the company.

TETRA TECHNOLOGIES INC (TTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. First Amendment to Term Loan Credit Agreement On October 2, 2026, TETRA Technologies, Inc. (the “Company”) entered into the First Amendment to Credit Agreement (the “First Amendment”), by and among the Company, as borrower, t

TETRA Technologies (TTI) stock fell 20.9% since reporting Q2 results, trading at $6.17. NESR (NESR) reported 59.1% revenue growth, beating estimates, but its stock dropped 15.5% to $24.52. ProPetro (PUMP) missed expectations, with revenue down 6.2%, and its stock fell 10.1% to $9.59. Oceaneering (OII) beat estimates with 10% revenue growth, stock flat at $44.97. Valaris (VAL) reported 12.4% revenue decline but beat EPS estimates, stock up 6.5% to $82.00.

Clear Street upgraded TETRA Technologies (TTI) to Buy with a $11.00 target, citing its Arkansas bromine project. TTI shares are down 36% YTD. Clear Street expects $400M revenue and $90M EBITDA from the project by 2030. Q2 revenue beat estimates at $185.7M, but Northland and Stifel lowered price targets.

John Angela D purchased 10,000 shares of TETRA TECHNOLOGIES INC (TTI) at $6.50 on 2026-09-02.

Northland reduced its price target for TETRA Technologies (NYSE:TTI) to $10.00 from $14.00, citing modest 2027 estimates. The stock is down 48% from its 52-week high. Analysts maintain a Strong Buy consensus. TETRA reported Q2 2026 revenue of $185.7M, beating estimates by 5.42%. The company also announced a lithium offtake agreement, reducing risk for future royalty streams.

TETRA Technologies (TTI) reported Q2 2026 revenue of $185.7 million, up 19% sequentially and 7% year over year, and adjusted EBITDA of $31.9 million. The company said international offshore revenues hit a 10-year high and that an equity offering reduced net debt to $28.7 million and net leverage to 0.4x. It also approved the Arkansas bromine project, with startup in early 2028.

Tetra Technologies (NYSE:TTI) reported Q2 results despite delayed Middle East shipments and higher third-party bromine costs. Water and Flowback Services revenue rose to $72.5M, up 12% QoQ and 13% YoY; adjusted EBITDA margin increased to 14.8%. The board approved a final investment decision for its Arkansas bromine facility, funded partly by ~$108M net equity proceeds. Tetra ended the quarter with $154.6M cash and $183.3M debt (net debt $28.7M).

TETRA Technologies reported Q2 2026 earnings call highlights, including 10-year highs in international and global offshore revenue, an FID for its Arkansas Bromine project, and a new completion fluid, TETRA Neptune Z-Lite. It expanded Oasis TDS desalination work, cited shipment delays from Middle East conflict, and noted an equity offering raising about $108 million net proceeds and net leverage at 0.4x.